Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.


Journal Article

Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer.

Full Text

Duke Authors

Cited Authors

  • Zhang, T; Armstrong, AJ

Published Date

  • October 15, 2015

Published In

Volume / Issue

  • 21 / 20

Start / End Page

  • 4505 - 4507

PubMed ID

  • 26307134

Pubmed Central ID

  • 26307134

International Standard Serial Number (ISSN)

  • 1078-0432

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-15-1613


  • eng

Conference Location

  • United States